Latest news

Adalvo expects to file 30 DCPs within 2023. Here is a glimpse on our exciting DCP filing plans for 2023.

Strategic partnership in Europe extended to cover five additional molecules in therapeutic categories including oncology and diabetes

Adalvo is pleased to announce that we have extended our strategic partnership with Zentiva, signing a licensing deal for three molecules, within Europe.

Adalvo and Frontier Biopharma/Zdravlje (“Frontier”) are pleased to announce their collaboration in several therapeutic areas for the markets of Central and Eastern Europe and the Balkans. Over the next months...

Adalvo is delighted to announce the successful DCP closure for Desmopressin 60mcg, 120mcg and 240mcg sub-lingual tablets. With this achievement, we believe we will be amongst the first companies to...

Adalvo is pleased to announce that we have successfully launched Vinorelbine soft gel capsules in Israel.

Adalvo is pleased to announce the addition of Ibrutinib 140mg, 280mg, 420mg & 560mg Film Coated Tablets to our product Portfolio.

Adalvo is delighted to announce the successful Pivotal BE study of our Dydrogesterone 10mg tablets. Our dossier is ready for immediate submission and we expect Adalvo to be amongst the first...

Adalvo is delighted to announce the successful DCP submission for Nintedanib 100mg & 150mg soft gel capsules. Our product is being developed in collaboration with our sister Company, which forms...

Adalvo is pleased to announce that we have partnered with MS Pharma, signing a licensing deal for Solifenacin + Tamsulosin in the MENA region.

Adalvo is pleased to announce the addition of Riociguat 0.5mg, 1mg, 1.5mg, 2mg & 2.5mg Film Coated Tabletsto our product Portfolio.

Adalvo is pleased to announce the successful launch of Enzalutamide Soft Gel Capsule in LATAM, fulfilling our commitment to our partners, and strengthening our presence in select LATAM countries.

Adalvo is pleased to announce that it has entered into a partnership with Aristo Pharma, to commercialize several dermatology products. This licensing and supply agreement includes a basket of five products...

Adalvo is pleased to announce the successful DCP closure for Dimethyl Fumarate120 and 240mghard capsules, and several market authorizations have been granted already. This is an additional wave of DCP approvals, where we...

As we strengthen our injection product pipeline, we are pleased to announce EU dossier readiness for Dalbavancin Injection will be complete by the end of 2022.  We now proceed to dossier...

Adalvo is pleased to announce the addition of Obeticholic Acid Tablets to our product Portfolio, a niche orphan product with strong growth potential.

We at Adalvo continue to strengthen our comprehensive arthritis medication portfolio, covering a unique selection for this indication. Arthritis is the swelling and tenderness of one or more joints. The...

One of our key targets is to deliver a diversified and competitive portfolio and support our partners in every step of their journey. We offer an array of women’s health...

Adalvo is pleased to announce the addition of Edoxaban film coated tablets to our product Portfolio. Dossier readiness for Edoxaban is expected in Q1 2024. Our product is being developed...

Following the successful completion of the acquisition of our first brand, Onsolis, we are pleased to announce that Adalvo will start supply of the product.

Adalvo is delighted to announce the successful MA approval of Solifenacin + Tamsulosin in various EU markets.